BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22471733)

  • 21. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.
    Abdelsamie AS; Bey E; Gargano EM; van Koppen CJ; Empting M; Frotscher M
    Eur J Med Chem; 2015 Oct; 103():56-68. PubMed ID: 26322835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and in vitro pharmacological evaluation of N-[(1-benzyl-1,2,3-triazol-4-yl)methyl]-carboxamides on d-secoestrone scaffolds.
    Szabó J; Bacsa I; Wölfling J; Schneider G; Zupkó I; Varga M; Herman BE; Kalmár L; Szécsi M; Mernyák E
    J Enzyme Inhib Med Chem; 2016 Aug; 31(4):574-9. PubMed ID: 26360618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
    Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
    Laplante Y; Rancourt C; Poirier D
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
    Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
    PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
    Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
    Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
    Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
    J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
    Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
    Ma X; Chui WK
    Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
    Lin SX; Poirier D; Adamski J
    Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
    Vyas VK; Variya B; Ghate MD
    Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
    Gunn D; Akuche C; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook J; Conrad P; Dixon B; Dumas J; Ehrlich P; Gane T; Joe T; Johnson J; Jordan J; Kramss R; Liu P; Levy J; Lowe D; McAlexander I; Natero R; Redman AM; Scott W; Seng T; Sibley R; Wang M; Wang Y; Wood J; Zhang Z
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3053-7. PubMed ID: 15890515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo.
    Li F; Zhu Z; Xue M; He W; Zhang T; Feng L; Lin S
    Drug Des Devel Ther; 2019; 13():757-766. PubMed ID: 30863015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.